| Literature DB >> 32864931 |
Ibrahim Halil Kurt1, Ömer Şen1, Mehmet Kuçükosmanoğlu1, Fatma Özge Salkın1, Örsan Deniz Urgun1, Şeyda Şahin1, Salih Çolak1, Salih Kılıç1.
Abstract
INTRODUCTION: Recently, the clinical significance of mild paravalvular aortic regurgitation (PAR) has been evaluated and suggested that it can be predictor of clinical outcomes. In our study, we aimed to investigate the interaction of aortic pulse wave velocity (PWV) and mild PAR and their effects on the functional status of patients after transcatheter aortic valve implantation (TAVI).Entities:
Keywords: Aortic Valve Insufficiency; Aortic Valve Stenosis; Blood Pressure; Pulse Wave Analysis; Reference Values; Regression Analysis; Transcatheter Aortic Valve Replacement
Mesh:
Substances:
Year: 2020 PMID: 32864931 PMCID: PMC7454626 DOI: 10.21470/1678-9741-2019-0454
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1Analysis of a patient. cDia=central diastolic pressure; CI=confidence interval; cPP=central pulse pressure; cSys=central systolic pressure; MAP=mean arterial pressure; PWA=pulse wave analysis; PWV=pulse wave velocity
Patients' baseline characteristics.
| Variables | NonePAR group (n=60) | MildPAR-nPWV group (n=23) | MildPAR-hPWV group (n=26) | |
|---|---|---|---|---|
| Age (years) | 75.5±4.5 | 76.8±4.5 | 81.1±5,1 | < 0.001 |
| Sex (male), n (%)* | 23 (38,3) | 11 (48.8) | 13 (50) | 0.966 |
| BMI (kg/m2) | 27±5,6 | 27±4.9 | 26±6.2 | 0.904 |
| Hypertension, n (%)* | 25 (41.7) | 7 (30.4) | 18 (69.2) | 0.015 |
| DM, n (%)* | 15 (25) | 6 (26.1) | 8 (30.8) | 0.417 |
| Smoking, n (%)* | 10 (16.7) | 5 (21.7) | 7 (26.9) | 0.548 |
| Previous CABG, n (%)* | 14 (23.3) | 6 (26.1) | 8 (30.8) | 0.859 |
| Coronary artery disease, n (%)* | 32 (53.3) | 10 (43.5) | 11 (42.3) | 0.341 |
| AF, n (%)* | 12 (20) | 6 (23) | 6 (26) | 0.234 |
| STS score (%) | 11.2±2.7 | 11.8±2.9 | 11.15±2.1 | 0.618 |
| Medication, n (%)* | ||||
| Aspirin | 43 (71.7) | 18 (69.2) | 17 (74) | 0.623 |
| Statin | 16 (26.6) | 8 (31) | 7 (30) | 0.186 |
| β-blocker | 28 (46.6) | 14 (54) | 12 (52.1) | 0.324 |
| ACE-I/ARB | 16 (26.6) | 9 (34.6) | 7 (30) | 0.254 |
| WBC count ('1000/pl) | 13.1±3.98 | 12.8±4.78 | 13.2±3.72 | 0.266 |
| Hemoglobin (mg/dl) | 11.1±1.62 | 10.9±1.85 | 11±1.36 | 0.522 |
| Platelet count ('109/l) | 188±68 | 176±52 | 196±44 | 0.346 |
| Creatinine (mg/dl) | 0.91±0.24 | 0.86±0.20 | 0.88±0.36 | 0.286 |
| Total cholesterol (mg/dl) | 192.2±28.6 | 186.8±33 | 189.3±25 | 0.428 |
| HDL-C (mg/dl) | 39.6±8.4 | 40.2±9.9 | 38.7±7.8 | 0.312 |
| LDL-C (mg/dl) | 127±35.5 | 132±29 | 125±41 | 0.218 |
| Triglyceride (mg/dl) | 135±65 | 125±86 | 140±115 | 0.313 |
X2
P<0,001 vs. MildPAR-hPWV group;
P<0.001 vs. MildPAR-hPWV group;
P=0.052;
P=0.019 vs. MildPAR-hPWV group
Significant P-values (P<0.05) are indicated in boldface ACE-I/ARB=angiotensin converting enzyme inhibitor/angiotensin II receptor blocker; AF=atrial fibrillation; ANOVA=analysis of variance; BMI=body mass index; CABG=coronary artery bypass grafting; DM=diabetes mellitus; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; MildPAR-hPWV=mild paravalvular aortic regurgitation with high pulse wave velocity; MildPAR-nPWV=mild paravalvular aortic regurgitation with normal pulse wave velocity; NonePAR=no paravalvular aortic regurgitation; STS=Society of Thoracic Surgeons; WBC=white blood cell
Fig. 2Distribution of NYHA classification within groups. MildPARhPWV= mild paravalvular aortic regurgitation with high pulse wave velocity; MildPAR-nPWV=mild paravalvular aortic regurgitation with normal pulse wave velocity; NonePAR=no paravalvular aortic regurgitation; NYHA=New York Heart Association
Fig. 3Aortic regurgitation index within groups. MildPAR-hPWV=mild paravalvular aortic regurgitation with high pulse wave velocity; MildPAR-nPWV=mild paravalvular aortic regurgitation with normal pulse wave velocity; NonePAR=no paravalvular aortic regurgitation
Patients' clinic, hemodynamic, and echocardiographic characteristics.
| Variables | NonePAR group (n=60) | MildPAR-nPWV group (n=23) | MildPAR-hPWV group (n=26) | |
|---|---|---|---|---|
| Pre-TAVI SBP (mmHg) | 121±16 | 119±14 | 123.1±13.4 | 0.765 |
| Post-TAVI SBP (mmHg) | 119±18 | 122±21 | 121±24 | 0.767 |
| Pre-TAVI DBP (mmHg) | 67.5±8.3 | 67±6.8 | 64.3±8.9 | 0.333 |
| Post-TAVI DBP (mmHg) | 68.4±8.2 | 68.2±8.6 | 66±8.2 | 0.346 |
| Pre-TAVI MAP (mmHg) | 91±9.2 | 88.7±8.2 | 85.6±10.4 | 0.112 |
| Post-TAVI MAP (mmHg) | 91.7±12 | 92.2±13 | 86.9±11 | 0.230 |
| Pre-TAVI PP (mmHg) | 51.5±12.9 | 50.8±12.6 | 60.2±8.9 | 0.018 |
| Post-TAVI PP (mmHg) | 50.8±12.7 | 54.8±15.5 | 59.6±15.6 | 0.067 |
| Pre-TAVI pulse (beat/min) | 72±13 | 68±9 | 68±15 | 0.369 |
| Post-TAVI pulse (beat/min) | 74±16 | 69±12 | 76±11 | 0.286 |
| Pre-TAVI AVA (cm2) | 0.75±0.9 | 0.74±0.07 | 0.76±0.11 | 0.891 |
| Post-TAVI AVA (cm2) | 2.08±0.27 | 2.11±0.18 | 2.14±1.9 | 0.842 |
| Pre-TAVI AVPG (mmHg) | 77±11 | 76±10 | 79±10.5 | 0.480 |
| Post-TAVI AVPG (mmHg) | 11±4 | 14±3 | 10±4 | 0.384 |
| Pre-TAVI AVMG (mmHg) | 47.1±6.2 | 46.5±5.5 | 48.5±7 | 0.344 |
| Post-TAVI AVMG (mmHg) | 5±3 | 7±4 | 6±3 | 0.524 |
| LVEF(%) | 55±10.4 | 54±9.6 | 55±7.6 | 0.756 |
| LVMI (g/m2) | 122.6±26 | 121.8±31 | 123±24 | 0.652 |
| Post-TAVI NYHA class, n(%) | 13 (21.7) | 4 (17.4) | 17 (64.4) | < 0.001 |
| Permanent pacemaker implantation, n (%) | 11 (19) | 5 (21.7) | 6 (23.1) | 0.654 |
| Pre-TAVI AR > Mild, n (%) | 7 (11.6) | 4 (15.3) | 3 (13) | 0.284 |
| AR index | 31.8±4.1 | 32.9±3.5 | 29.3±4.7 | 0.010 |
| Pre-TAVI PWV (m/sec) | 10.2±1.7 | 9.7±1.8 | 12.2±1.2 | < 0.001 |
| Post-TAVI PWV (m/sec) | 10±1.7 | 9.6±1.9 | 12.3±1.4 | < 0.001 |
| Nt-ProBNP (pg/ml) | 613±448 | 572±414 | 913±438 | 0.009 |
Significant P-values (P<0.05) are indicated in boldface.
P=0,070 vs. MildPAR-hPWV group;
P=0.023 vs. MildPAR-hPWV group
P=0.046 vs. MildPAR-hPWV group;
P=0.012 vs. MildPAR-hPWV group
P=0.015 vs. MildPAR-hPWV group;
P =0.026 vs. MildPAR-hPWV group
ANOVA=analysis of variance; AR=aortic regurgitation; AVA=aortic valve area; AVMG=aortic valve mean gradient; AVPG=aortic valve peak gradient; DBP=diastolic blood pressure; LVEF=left ventricular ejection fraction; LVMI=left ventricular mass index; MAP=mean arterial pressure; MildPAR-hPWV=mild paravalvular aortic regurgitation with high pulse wave velocity; MildPAR-nPWV=mild paravalvular aortic regurgitation with normal pulse wave velocity; NonePAR=no paravalvular aortic regurgitation; NT-proBNP=N-terminal pro-brain natriuretic peptide; NYHA=New York Heart Association; PP=pulse pressure; PWV=pulse wave velocity; SBP=systolic blood pressure; TAVI=transcatheter aortic valve implantation
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| ACE-I/ARB | = Angiotensin converting enzyme inhibitor/angiotensin II receptor blocker | LVMI | = Left ventricular mass index | |
| AF | = Atrial fibrillation | MAP | = Mean arterial pressure | |
| ANOVA | = Analysis of variance | MildPAR-hPWV | = Mild paravalvular aortic regurgitation with high pulse wave velocity | |
| AR | = Aortic regurgitation | |||
| ARI | = Aortic regurgitation index | MildPAR-nPWV | = Mild paravalvular aortic regurgitation with | |
| AS | = Aortic stenosis | NonePAR | = No paravalvular aortic regurgitation | |
| AVA | = Aortic valve area | NT-proBNP | = N-terminal pro-brain natriuretic peptide | |
| AVMG | = Aortic valve mean gradient | NYHA | = New York Heart Association | |
| AVPG | = Aortic valve peak gradient | AR | = Paravalvular aortic regurgitation | |
| BMI | = Body mass index | PP | = Pulse pressure | |
| CABG | = Coronary artery bypass grafting | PSAX | = Parasternal short axis | |
| cDia | = Central diastolic pressure | PWA | = Pulse wave analysis | |
| CI | = Confidence interval | PWV | = Pulse wave velocity | |
| cPP | = Central pulse pressure | SBP | = Systolic blood pressure | |
| cSys | = Central systolic pressure | STS | = Society of Thoracic Surgeons | |
| DBP | = Diastolic blood pressure | TAVI | = Transcatheter aortic valve implantation | |
| DM | = Diabetes mellitus | TEE | = Transesophageal echocardiography | |
| HDL-C | = High-density lipoprotein cholesterol | TTE | = Transthoracic echocardiography | |
| LDL-C | = Low-density lipoprotein cholesterol | VARC | = Valve Academic Research Consortium | |
| LVEF | = Left ventricular ejection fraction | WBC | = White blood cell | |
| Authors' roles & responsibilities | |
|---|---|
| IHK | Substantial contributions to the conception or design of the work; final approval of the version to be published |
| OS | Substantial contributions to the conception or design of the work; final approval of the version to be published |
| MK | Analysis of data for the work; final approval of the version to be published |
| FOS | Interpretation of data for the work; final approval of the version to be published |
| ODU | Interpretation of data for the work; final approval of the version to be published |
| SS | Acquisition of data for the work; final approval of the version to be published |
| SC | Acquisition of data for the work; final approval of the version to be published |
| SK | Analysis of data for the work; final approval of the version to be published |